Cognitive Decline and Its Associated Factors in Patients with Major Depressive Disorder.
Mini International Neuropsychiatric Interview
Montreal Cognitive Assessment
cognitive decline
major depressive disorder
outpatients
Journal
Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525
Informations de publication
Date de publication:
25 Mar 2023
25 Mar 2023
Historique:
received:
30
12
2022
revised:
20
02
2023
accepted:
21
03
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
Major Depressive Disorder (MDD) is a significant and common mental health problem occurring worldwide. Cognitive decline is frequently observed during acute and residual phases of MDD, contributing significantly to functional impairment. The aim of this study was to determine the clinical profile and correlates of cognitive decline amongst adult outpatients with MDD. The survey was cross-sectional in design. A systematic random sampling method was used to recruit patients. Confirmation of MDD was achieved by using the Mini International Neuropsychiatric Interview (M.I.N.I 7.0). Cognitive decline was measured using the Montreal Cognitive Assessment (MoCA). Descriptive analysis was performed, followed by univariate and multiple logistic regression analyses. Out of 245 patients, 32.7% ( Cognitive decline is a prevalent condition among outpatients with MDD. Clinicians need to be cognizant about measures of cognition and related risk factors. Timely control of both depression and medical comorbidities would be a reasonable approach to improve functional outcomes in MDD patients.
Sections du résumé
BACKGROUND
BACKGROUND
Major Depressive Disorder (MDD) is a significant and common mental health problem occurring worldwide. Cognitive decline is frequently observed during acute and residual phases of MDD, contributing significantly to functional impairment. The aim of this study was to determine the clinical profile and correlates of cognitive decline amongst adult outpatients with MDD.
METHODS
METHODS
The survey was cross-sectional in design. A systematic random sampling method was used to recruit patients. Confirmation of MDD was achieved by using the Mini International Neuropsychiatric Interview (M.I.N.I 7.0). Cognitive decline was measured using the Montreal Cognitive Assessment (MoCA). Descriptive analysis was performed, followed by univariate and multiple logistic regression analyses.
RESULTS
RESULTS
Out of 245 patients, 32.7% (
CONCLUSIONS
CONCLUSIONS
Cognitive decline is a prevalent condition among outpatients with MDD. Clinicians need to be cognizant about measures of cognition and related risk factors. Timely control of both depression and medical comorbidities would be a reasonable approach to improve functional outcomes in MDD patients.
Identifiants
pubmed: 37046877
pii: healthcare11070950
doi: 10.3390/healthcare11070950
pmc: PMC10094268
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Can J Psychiatry. 2014 Dec;59(12):649-54
pubmed: 25702365
Transl Psychiatry. 2022 Nov 8;12(1):468
pubmed: 36347845
Expert Opin Drug Saf. 2022 May;21(5):673-690
pubmed: 34964415
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1387-92
pubmed: 12552118
Annu Rev Neurosci. 2009;32:57-74
pubmed: 19400725
Front Psychiatry. 2018 Dec 04;9:655
pubmed: 30564155
J Affect Disord. 2005 Dec;89(1-3):125-35
pubmed: 16324752
J Affect Disord. 2015 Jan 15;171:105-10
pubmed: 25303026
Bipolar Disord. 2012 Mar;14(2):198-205
pubmed: 22420595
Psychol Med. 2009 May;39(5):725-33
pubmed: 18667097
Aging Dis. 2013 Sep 20;4(6):329-36
pubmed: 24307966
J Neuropsychiatry Clin Neurosci. 2006 Spring;18(2):217-25
pubmed: 16720799
Psychol Med. 2014 Jul;44(10):2029-40
pubmed: 24168753
Psychol Med. 2011 Jun;41(6):1165-74
pubmed: 20932356
Am J Psychiatry. 2008 Jun;165(6):731-9
pubmed: 18381906
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
J Neurosci. 1999 Jun 15;19(12):5034-43
pubmed: 10366636
Psychiatry Res. 2017 Jul;253:333-337
pubmed: 28415018
Folia Phoniatr Logop. 2013;65(2):49-54
pubmed: 23941972
Drugs. 2016 Nov;76(17):1675-1682
pubmed: 27807822
Front Psychiatry. 2020 Apr 24;11:280
pubmed: 32390877
J Affect Disord. 2022 Aug 1;310:369-376
pubmed: 35504401
Biol Psychiatry. 2004 Nov 1;56(9):640-50
pubmed: 15522247
Depress Anxiety. 2013 Jun;30(6):515-27
pubmed: 23468126
Eur Neuropsychopharmacol. 2012 Jan;22(1):1-16
pubmed: 21723712
J Affect Disord. 2018 May;232:237-242
pubmed: 29499506
Pharmacol Ther. 2015 Jan;145:43-57
pubmed: 25016186
J Psychiatr Res. 2011 Jan;45(1):15-23
pubmed: 21220074
Psychiatry Clin Neurosci. 2009 Jun;63(3):392-400
pubmed: 19566772
J Int Neuropsychol Soc. 2002 Mar;8(3):448-60
pubmed: 11939702
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Lancet Psychiatry. 2019 Oct;6(10):851-861
pubmed: 31422920
Front Psychiatry. 2018 Oct 11;9:493
pubmed: 30364225
Arch Clin Neuropsychol. 2006 Dec;21(8):787-96
pubmed: 17030111
Ann Clin Psychiatry. 2013 May;25(2):135-40
pubmed: 23638444
Am J Geriatr Psychiatry. 2014 Dec;22(12):1633-41
pubmed: 24680502
Int J Neuropsychopharmacol. 2015 Jul 25;19(2):
pubmed: 26209859
Psychiatry Investig. 2018 Jan;15(1):70-77
pubmed: 29422928
Asia Pac Psychiatry. 2019 Mar;11(1):e12346
pubmed: 30511420
J Affect Disord. 2001 Oct;66(2-3):225-36
pubmed: 11578676